Xencor, Inc. (NASDAQ:XNCR) Receives $24.86 Average Price Target from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $30.7143.

Several equities analysts recently commented on the stock. Wedbush upped their price target on shares of Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their price target on shares of Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Cantor Fitzgerald boosted their price objective on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Truist Financial lowered their price objective on shares of Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th.

Xencor Stock Performance

NASDAQ:XNCR opened at $26.61 on Tuesday. The firm has a 50-day moving average price of $21.28 and a two-hundred day moving average price of $15.43. Xencor has a twelve month low of $8.19 and a twelve month high of $30.61. The company has a market capitalization of $1.98 billion, a P/E ratio of -12.26 and a beta of 0.88.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.Xencor’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.41) EPS. On average, equities research analysts predict that Xencor will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its holdings in Xencor by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 1,026 shares during the last quarter. Cerity Partners LLC increased its holdings in Xencor by 3.8% during the 4th quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 1,143 shares during the last quarter. State of Tennessee Department of Treasury increased its holdings in Xencor by 6.2% during the 2nd quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 1,784 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Xencor by 3.3% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 2,256 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.